Verification of B-lymphocyte activating factor’s involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease

Table 1 Clinical characteristics of the enrolled patients

Clinical parameters	NASH (n = 25)	CLD-C (n = 22)	p value
Age (y.o.)	53.7 ± 13.1 (21–76)	59.1 ± 7.4 (39–69)	0.1192
Gender (male/female)	(8/17)	(10/12)	0.3824
Staging (F₁/F₂/F₃/F₄)	14/1/9/1	9/8/3/2	0.7361
Steatosis (gr0/gr1/gr2/gr3)	0/6/8/11	8/10/4/0	<0.0001
BMI	27.4 ± 4.5 (16.0–35.3)	23.8 ± 3.62 (17.0–33.5)	0.0035
HOMA-IR value	4.95 ± 3.11 (1.34–13.00)	1.99 ± 1.25 (0.53–5.74)	<0.0001
Prevalence of ANA	10 (40%)	9 (41%)	0.9999

ISSN: 1758-5996